EE162 Cost-Effectiveness of Obinutuzumab Plus Bendamustine and Followed by Obinutuzumab Maintenance Therapy in Chinese Patients With Relapse and Refractory Follicular Lymphoma
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.412
https://www.valueinhealthjournal.com/article/S1098-3015(22)02616-X/fulltext
Title :
EE162 Cost-Effectiveness of Obinutuzumab Plus Bendamustine and Followed by Obinutuzumab Maintenance Therapy in Chinese Patients With Relapse and Refractory Follicular Lymphoma
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02616-X&doi=10.1016/j.jval.2022.09.412
First page :
Section Title :
Open access? :
No
Section Order :
12216